The latest news on osimertinib/osimertinib medical insurance reimbursement in 2024

Osimertinib is a targeted treatment for non-small cell lung cancer (NSCLC), specifically for patients with EGFR (epidermal growth factor receptor) mutations. It is a third-generation EGFR inhibitor, also known as AZD9291, with higher selectivity and stronger inhibitory effect, and can effectively overcome some common EGFR resistance mutations.

The original drug of Osimertinib/Osimertinib has been launched in the domestic market and has been included in the national medical insurance system, allowing patients to purchase it conveniently domestically. Its selling price is roughly in the range of three to four thousand yuan. Regarding specific drug pricing and medical insurance reimbursement details, patients are advised to consult their local hospital or pharmacy to obtain the most accurate information. In addition, compared with domestic prices, the prices of foreign generic drugs are more affordable, especially those listed in Laos and Bangladesh, which usually cost only a few hundred yuan, which is far lower than domestic levels. It is worth mentioning that the ingredients of these generic drugs are highly consistent with the original drugs.

Osimertinib/Osimertinib is unique in its highly selective inhibition of the EGFR T790M mutation. EGFR T790M mutation is one of the main mechanisms leading to NSCLC drug resistance. In contrast, traditional first- and second-generation EGFR inhibitors are not effective in overcoming this resistance.

Clinical trials have shown that osimertinib/osimertinib has shown significant efficacy in the treatment of EGFR mutation-positive advanced NSCLC patients. It can prolong the progression-free survival of patients and has lower toxic and side effects than traditional treatment options.

In addition,osimertinib/Osimertinib is also very convenient to administer. It is usually given as an oral drug that can be treated at home without the need for hospitalization or intravenous injection. This is of great significance for improving patients' quality of life and convenience of treatment.

Althoughosimertinib/osimertinib has demonstrated significant efficacy in the treatment ofNSCLC, some patients may develop drug resistance. Therefore, researchers are working hard to find more effective treatment strategies to further improve patient survival and prognosis. Overall, the emergence of osimertinib/osimertinib has brought new hope to EGFRpositive NSCLC patients and plays an important role in clinical practice.